Natera, Inc. $NTRA is Eagle Health Investments LP’s 3rd Largest Position

Eagle Health Investments LP trimmed its position in shares of Natera, Inc. (NASDAQ:NTRA) by 13.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 203,664 shares of the medical research company’s stock after selling 32,300 shares during the period. Natera comprises 8.6% of Eagle Health Investments LP’s investment portfolio, making the stock its 3rd largest position. Eagle Health Investments LP’s holdings in Natera were worth $32,784,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Zweig DiMenna Associates LLC boosted its stake in shares of Natera by 6.8% in the 3rd quarter. Zweig DiMenna Associates LLC now owns 132,500 shares of the medical research company’s stock valued at $21,329,000 after purchasing an additional 8,400 shares in the last quarter. GSA Capital Partners LLP lifted its stake in shares of Natera by 11.4% in the 3rd quarter. GSA Capital Partners LLP now owns 14,820 shares of the medical research company’s stock valued at $2,386,000 after acquiring an additional 1,515 shares during the last quarter. Rothschild Investment LLC purchased a new stake in Natera during the 3rd quarter valued at about $323,000. denkapparat Operations GmbH grew its holdings in shares of Natera by 46.7% in the third quarter. denkapparat Operations GmbH now owns 3,632 shares of the medical research company’s stock worth $585,000 after purchasing an additional 1,156 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its stake in shares of Natera by 9.4% in the third quarter. JPMorgan Chase & Co. now owns 11,628,914 shares of the medical research company’s stock worth $1,871,914,000 after buying an additional 1,003,129 shares during the period. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on NTRA shares. Citigroup initiated coverage on shares of Natera in a research report on Wednesday, January 7th. They set a “buy” rating and a $300.00 price target for the company. Wells Fargo & Company increased their price objective on Natera from $190.00 to $205.00 and gave the stock an “equal weight” rating in a report on Monday, December 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Natera in a research note on Thursday, January 22nd. BTIG Research raised their price target on Natera from $230.00 to $260.00 and gave the stock a “buy” rating in a research note on Friday, December 5th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Natera from $250.00 to $260.00 and gave the company an “overweight” rating in a research report on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $249.20.

Natera Stock Up 2.4%

Natera stock opened at $211.25 on Wednesday. Natera, Inc. has a twelve month low of $125.38 and a twelve month high of $256.36. The company has a market capitalization of $29.22 billion, a P/E ratio of -92.25 and a beta of 1.64. The stock’s 50 day moving average is $229.23 and its 200 day moving average is $200.54.

Insider Activity

In other Natera news, CFO Michael Burkes Brophy sold 6,939 shares of the firm’s stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $227.83, for a total transaction of $1,580,912.37. Following the completion of the sale, the chief financial officer directly owned 52,120 shares in the company, valued at approximately $11,874,499.60. This trade represents a 11.75% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Solomon Moshkevich sold 1,639 shares of the company’s stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $230.77, for a total transaction of $378,232.03. Following the completion of the transaction, the insider owned 137,847 shares in the company, valued at approximately $31,810,952.19. This represents a 1.18% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 450,787 shares of company stock valued at $105,376,360. Company insiders own 5.63% of the company’s stock.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.